Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000471628 | SCV000551808 | pathogenic | Retinoblastoma | 2016-11-16 | criteria provided, single submitter | clinical testing | Loss-of-function variants in RB1 are known to be pathogenic. This particular variant has been reported in the literature in an individual with retinoblastoma (PMID: 12541220). For these reasons, this variant has been classified as Pathogenic. This sequence change creates a premature translational stop signal at codon 443 (p.Ser443*) of the RB1 gene. It is expected to result in an absent or disrupted protein product. |
Ambry Genetics | RCV000492335 | SCV000580811 | pathogenic | Hereditary cancer-predisposing syndrome | 2014-05-30 | criteria provided, single submitter | clinical testing | The p.S443* pathogenic mutation (also known as c.1328C>A) located in coding exon 13 of the RB1 gene, results from a C to A substitution at nucleotide position 1328. This changes the amino acid from a serine to a stop codon within coding exon 13. This alteration was previously identified in an individual with bilateral retinoblastoma (Richter S, Am. J. Hum. Genet. 2003 Feb; 72(2):253-69). In addition to the clinical data presented in the literature, since premature stop codons are typically deleterious in nature, this alteration is interpreted as a disease-causing mutation (ACMG Recommendations for Standards for Interpretation and Reporting of Sequence Variations. Revision 2007. Genet Med. 2008;10:294). |